VIM and cystic fibrosis: To explore a true phenotypic shift at a structural protein level, we stained CF and non-CF pancreata with the classical mesenchymal marker vimentin, a type III intermediate filament core to the EMT process (Usman et al. 2021), to determine presence/absence in endocrine cells and explore potential spatial associations with pancreatic fibrosis.